COPY

PTO-14	49 REP	RODUCED	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716
ı		SECOND SUPPLEMENTAL ATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et	al.
		April 2, 2003	FILING DATE	CONFIRMATION NO. GROUP
ļ	(Use s	everal sheets if necessary)	March 30, 2001	CONFIRMATION NO. 7248 CONFIRMATION NO. 7248
·		T	U.S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
M	ВА	2,470,296	05/17/49	Fields
	ВВ	2,533,065	12/05/50	Taplin et al.
	ВС	2,992,645	07/18/61	Fowler
	BD	3,781,230	12/25/73	Vassiliades et al.
	BE	3,957,965	05/18/76	Harley et al.
	BF	4,009,280	02/22/77	Macarthur et al.
	BG	4,089,800	05/16/78	Temple
	вн	4,161,516	07/17/79	Bell
	ві	4,173,488	11/06/79	Vassiliades et al.
	BJ	4,272,398	06/09/81	Jaffe
	вк	4,352,883	10/05/82	Lim
	BA2	4,391,909	07/05/83	Lim
	BB2	4,466,442	08/21/84	Hilmann et al.
	BC2	4,480,041	10/30/84	Myles et al.
	BD2	4,524,769	06/25/85	Wetterlin
	BE2	4,572,203	02/25/86	Feinstein
	BF2	4,590,206	05/20/86	Forrester et al.
	BG2	4,615,697	10/07/86	Robinson
	вн2	4,679,555	07/14/87	Sackner
	BI2	4,741,872	05/03/88	De Luca et al.
	BJ2	4,743,545	05/10/88	Torobin
	BK2	4,774,958	10/04/88	Feinstein
	BA3	4,789,550	12/06/88	Hommel et al.
	BB3	4,818,542	04/04/89	De Luca et al.
	всз	4,847,091	07/11/89	Illum
	BD3	4,855,144	08/08/89	Leong et al.
J/	BE3	4,857,311	08/15/89	Domb et al.
EXAMIN	IER	M. (DATE CONSIDERED 2/12/0	ni y

P20 1				Sheet 2 of
P10-14	449 RE	SECOND SUPPLEMENTAL	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716
r	INFOR	MATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards,	et al.
		April 2, 2003	FILING DATE	
	(Use	several sheets if necessary)	March 30, 2001	7248 GROUP
EXAM-	_		U.S. PATENT DOCUMENTS	
INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
M	BF3	4,861,627	08/29/89	Mathiowitz et al.
M	BG3	4,865,789	09/12/89	Castro et al.
	внз	This reference number intentionally left blank		
M	BI3	4,904,479	02/27/90	Illum
	BJ3	4,917,119	04/17/90	Potter et al.
	BK3	4,963,297	10/16/90	Madden
	BA4	4,976,968	12/11/90	Steiner
n	BB4	4,994,281	02/19/91	Muranishi et al.
	BC4	This reference number intentionally left blank		
M	BD4	5,033,463	07/23/91	Cocozza
1-1	BE4	5,064,650	11/12/91	Lew
	BF4	5,069,936	12/03/91	Yen
1-1	BG4	5,075,109	12/24/91	Tice et al.
 	BH4	5,100,669	03/31/92	Hyon et al.
	BI4	5,123,414	06/23/92	Unger
I I	BJ4	5,145,684	09/08/92	Liversidge et al.
E	BK4	5,160,745	11/03/92	De Luca et al.
В	BA5	5,169,871	12/08/92	Hughes et al.
B	3B5	5,174,988	12/29/92	Mautone et al.
В	3C5	5,195,520	03/23/93	Schlief et al.
BI	D5	5,204,108	04/20/93	Illum
BI	E5	5,204,113	04/20/93	Hartley et al.
BE	F5 !	5,260,306	11/09/93	Boardman et al.
BG	$\overline{}$	5,271,961	12/21/93	Mathiowitz et al.
ВН	_	5,306,483 /	04/26/94	Mautone
BI		5,327,883	07/12/94	Williams et al.
MINER <		THO:	DATE CONSIDERED 2/12	·

<u></u>	FO-1	449 PF	PRODUCED		Sheet 3 o	£ 16
	.0-1	449 KE		ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	
	1	INFOR	SECOND SUPPLEMENTAL MATION DISCLOSURE CITATION	APPLICANT		
			IN AN APPLICATION	David A. Edwards, e	t al.	
		/IIaa	April 2, 2003	FILING DATE March 30, 2001	CONFIRMATION NO. GROUP	
-			several sheets if necessary)	_ i	7248 1615	
11	ZAM-	1		U.S. PATENT DOCUMENTS		
IN IN TI			DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME	
	1	BJ5	5,334,381	08/02/94	Unger	
		BK5	5,340,587	08/23/94	Milhalko et al.	
		BA6	5,352,435	10/04/94	Unger	_
		BB6	5,384,133	01/24/95	Boyes et al.	\dashv
		BC6	5,393,524	02/28/95	Quay	\dashv
		BD6	5,407,609	04/18/95	Tice et al.	\dashv
	Ĺ	BE6	5,456,917	10/10/95	Wise et al.	\dashv
		BF6	5,466,841	11/14/98	Horrobin et al.	\dashv
		BG6	5,482,946	01/09/96	Clark et al.	\dashv
		вн6	5,518,709	05/21/96	Sutton et al.	\dashv
		BI6	5,518,998	05/21/96	Bäckström et al.	-
		ВЈ6	5,551,489	09/03/96	Trofast et al.	
		BK6	5,580,575	12/03/96	Unger et al.	\dashv
		BA7	5,607,695	03/04/97	Ek et al.	\dashv
		BB7	5,607,915	03/04/97	Patton	\dashv
	\perp	BC7	5,612,053	03/18/97	Baichwal et al.	\dashv
	\perp	BD7	5,614,216	03/25/97	Janoff	╢
	\perp	BE7	5,654,007	08/05/97	Johnson	\dashv
\perp		BF7	5,690,954	11/25/97	Illum	\parallel
\perp	1	BG7	5,698,721	12/16/97	Heath	\parallel
	1	BH7	5,707,644	01/13/98	Illum	\parallel
4	Į.	BI7	5,709,884	01/20/98	Trofast et al.	1
_	Į Ē	3J7	5,780,014	07/14/98	Eljamal	\parallel
_	+-		5,795,594	08/18/98	York et al.	1
4	В	BA8	5,804,212	09/08/98	Illum	1
<u> </u>			5,814,607	09/29/98	Patton	1
IMAX	NER	_	M	DATE CONSIDERED	lack	1 _
				2/12	707	

٠,

E

٠,

PTO-144	9 REPROD	DUCED	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716
IN	FORMAT	ECOND SUPPLEMENTAL FION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et	al.
		April 2, 2003	FILING DATE	CONFIRMATION NO. GROUP
(1	Use sev	veral sheets if necessary)	March 30, 2001	7248 1615
			U.S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
m	BC8	5,830,853	11/03/98	Bāckström, et al.
M	BD8	5,851,453	12/22/98	Hanna, et al.
	BE8	This reference number intentionally left blank		
M	BF8	5,874,063	02/23/99	Briggner et al.
	BG8	This reference number intentionally left blank		
M	вна	5,885,613	03/23/99	Holland et al.
	BI8	5,902,802	05/11/99	Heath
	вј8	5,922,354	07/13/99	Johnson
m	BK8	5,928,469	07/27/99	Franks et al.
	BA9	This reference number intentionally left blank		
	BB9	This reference number intentionally left blank		
	всэ	This reference number intentionally left blank		
M	BD9	5,993,783	11/30/99	Eljamal
	BE9	This reference number intentionally left blank		
	BF9	This reference number intentionally left blank		
	BG9	This reference number intentionally left blank		
M	внэ	6,019,968	02/01/00	Platz
	BI9	This reference number intentionally left blank		
M	вј9	6,051,256	04/18/00	Platz
M	вкэ	6,063,138	05/16/00	Hanna et al.
	BA10	This reference number intentionally left blank		
M	BB10	6,080,721	06/27/00	Patton .
	BC10	This reference number intentionally left blank		
EXAMIN	ER	M	DATE CONSIDERED 2/12/	64

PTO-14	449 REF	PRODUCED	ATTORNEY DOCKET NO. 2685.1003-008	Sheet s APPLICATION NO.
	INFORM	SECOND SUPPLEMENTAL MATION DISCLOSURE CITATION		09/822,716
		IN AN APPLICATION	David A. Edwards,	et al.
April 2, 2003 (Use several sheets if nece			FILING DATE	CONFIRMATION NO. GROUP
	(Use s	several sheets if necessary)	March 30, 2001	7248 1615
EXAM-	T		U.S. PATENT DOCUMENTS	
INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
M	BD10	6,103,270	08/15/00	Johnson
M	BE10	6,123,936	09/26/00	Platz
	BF10	intentionally left blank		
M	BG10	6,136,346	10/24/00	Eljamal
1_	вніо	6,153,224	11/28/02	Staniforth
	BI10	6,187,330 B1	02/13/01	Wang et al.
-	BJ10	6,187,344 B1	02/13/01	Eljamal
\vdash	BK10	6,231,851 B1	05/15/01	Platz
$\vdash \downarrow$	BA11	6,258,341 B1	07/10/01	Foster
	BB11	6,303,582 B1	10/16/01	Eljamal
	BC11	6,309,671 B1	10/30/01	Foster
-+	BD11	6,315,983 B1	11/13/01	Eistetter
	BE11	6,358,530 B1	03/19/02	Eljamal
_	BF11	6,426,210 Bl	07/30/02	Franks et al.
	BG11	6,433,040 B1	08/13/02	Dellamary et al.
	BH11	This reference number intentionally left blank		
1	3111	US2002/0052310 A1	05/02/02	Edwards et al.
	_			
_				
_				
_				
\perp				
\perp	\bot			
				T
MINER		1911	DATE CONSIDERED	
		11110	2//	12/04

Sheet 6 of 16 PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 2685.1003-008 09/822,716 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION APPLICANT IN AN APPLICATION David A. Edwards, et al. April 2, 2003 FILING DATE CONFIRMATION NO. GROUP March 30, 2001 (Use several sheets if necessary) 7248 1615 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER SUB-TRANSLATION DATE COUNTRY CLASS CLASS YES BL WO 80/02365 13/11/80 PCT BM WO 86/06959 04/12/86 PCT WO 88/04556 30/06/88 PCT BO WO 88/09163 01/12/88 PCT ВP WO 91/04732 18/04/91 PCT ВО WO 91/06286 16/05/91 PCT BL₂ WO 91/06287 16/05/91 PCT M BM2 WO 91/12823 05/09/91 PCT BN2 This reference number intentionally left blank WO 92/18164 29/10/92 PCT BP2 WO 92/21382 10/12/92 PCT B02 WO 93/25221 23/12/93 PCT BL3 WO 94/04133 03/03/94 PCT вмз WO 94/07514 14/04/94 PCT BN3 WO 94/08627 28/04/94 PCT WO 94/16739 04/08/94 PCT BP3 WO 95/00127 05/01/95 PCT BO3 WO 95/07072 16/03/95 PCT BL4 WO 95/24183 14/09/95 PCT BM4 WO 95/31479 23/11/95 PCT (Platz) BN4 WO 95/35097 28/12/95 PCT **BO4** WO 96/09814 04/04/96 PCT BP4 This reference number intentionally left blank MBQ4 WO 96/23485 08/08/96 PCT BL5 WO 96/32096 17/10/96 PCT (Eljamal) BM5 WO 96/32116 17/10/96 PCT (Eljamal) BN5 WO 96/32149 17/10/96 PCT (Platz) EXAMINER DATE CONSIDERED 2/12/04

II PIC	0-1449 1	REPRODUCED							heet	7 of 1	5
					ATTORNEY DOCKET NO. 2685.1003-008				ои ио		
11		SECOND SUPPLEME	ENTAL		2003.1003-008		09/	822,	716		
-	•	INFORMATION DISCLOSUR IN AN APPLICAT	E CI	TATION	APPLICANT						
1					David A. Edwards,	et	al.				
		April 2, 200	3		FILING DATE	_				т	
\parallel		(Use several sheets if	neces	sary)	March 30, 2001		CONFI NO.	RMAT:	ION	GROU 161	
							7248	}		1 101	5
-	7			FOREI	N PATENT DOCUMENTS						
1		DOCUMENT NUMBE	æ	DATE				7	UB-	TRAN	ICI NO
<u> </u>				JAIL	COUNTRY	١	LASS		LASS	YES	
N	Во	5 WO 96/40963		19/12/9	P.C.	-		+		├	
	BP.			 			1		1	1	
 		WO 96/418/3		27/12/9	5 PCT						\top
1	BQ:	WO 97/03649		06/02/97	PCT	+	+	+-	┼──		+
M	BLe	WO 97/36574		09/10/97	PCT	+-	+	-	}	<u></u> _	4
	ВМ6			+ , 3 /		+-					\perp
		intentionally left blank	1				1	ľ			
M	BN6	WO 98/16205		23/04/98	DOM: (5	+-	╁	<u> </u>			
1	B06	WO 98/29096			(5 15 2 2 1)		\perp				
+	+			09/07/98	PCT (Gordon)						
—	BP6	WO 98/29098		09/07/98	PCT (Gordon)	1		-			+
	BQ6	WO 98/29140		09/07/98	PCT (Gordon)	+-		\dashv			+-
M	BL7	WO 98/29141		09/07/98	 	+		\dashv			\bot
	BM7	This reference number	\dashv		PCT (Gordon)	Ш	\perp				
	L	intentionally left blank			1						T
\mathcal{O}	BN7	WO 98/51278	-	19/11/98	DOT	\vdash			\dashv		L
1	BO7	WO 99/16419			PCT		\bot				
+-			- 0	8/04/99	PCT						
	BP7	WO 99/16420	_ 0	8/04/99	PCT	\neg	$\neg \uparrow$	\top	-		-
	BQ7	WO 99/16421	0	8/04/99	PCT	+	+-	+-			<u> </u>
1 1	BL8	WO 99/16422				4	\bot				
n	BM8	<u> </u>		8/04/99	PCT	_		1	- 1		
		WO 99/66903	29	9/12/99	PCT	\top		1			
- 1	BN8	This reference number	1			+	+	+-	-		
20	вов	intentionally left blank									
		WO 00/15262	23	3/03/00	PCT (Clark)	1	\top	1-	+		
	BP8	WO 00/21594	20	/04/00	PCT (Clark)	+-	+	 	-+-		
	BQ8	WO 00/33811		/06/00		+-	+-	<u> </u>			
1	BL9	WO 01/00312 A1	+		PCT						
-+			04	/01/01	PCT (Bennett)				T		
_	ВМ9	WO 01/13891 A3	01,	/03/01	PCT	T^-	$\dagger \dagger$		+-		
7 t	3N9	WO 01/32144 A1	10	/05/01	PCT (Lechuga-	+-	+		-		
<u> </u>			/		PCT (Lechuga- Ballesteros)				1		
						+-	+		-		
MINER	₹	DAN					L'	_			l
	_	-T////		ļ	PATE CONSIDERED 2/12/	, /					$\neg \parallel$

PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 2685.1003-008 09/822,716 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION APPLICANT IN AN APPLICATION David A. Edwards, et al. April 2, 2003 FILING DATE CONFIRMATION NO. GROUP (Use several sheets if necessary) March 30, 2001 7248 1615 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER SVB-TRANSLATION DATE COUNTRY CLASS CLASS YES NO BO9 WO 02/09669 A3 07/02/00 PCT (Snyder) BP9 WO 02/11695 A3 14/02/02 PCT (Stevenson) BQ9 WO 02/054868 A2 18/07/02 PCT (Weickert) BL10 WO 02/055101 A2 18/07/02 PCT (Hastedt) BM10 WO 02/087542 A1 07/11/02 PCT (Bot) BN10 EP 0 072 046 A1 16/02/03 EPO BO10 EP 0 213 303 B1 04/09/91 EPO EP 0 257 915 A1 02/03/88 EPO BO10 EP 0 257 956 B1 20/05/92 **EPO** BL11 EP 0 324 938 A1 26/07/89 EPO BM11 EP 0 335 133 A2 04/10/89 EPO BN11 EP 0 458 745 A1 14/05/91 EPO B011 EP 0 510 731 A1 28/10/92 EPO BP11 EP 0 634 166 A1 18/01/95 EPO BQ11 EP 0 656 206 A1 07/06/95 EPO BL12 1 288 583 17/11/69 GB BM12 1,300,009 05/05/92 Canada BN12 1,302,258 02/06/92 Canada BO12 2,058,428 05/09/00 Canada BP12 2,085,884 30/12/91 Canada BQ12 2,111,002 22/08/00 Canada BL13 2,126,244 26/09/00 Canada BM13 2,166,108 05/01/95 Canada BN13 2,170,394 02/03/95 Canada EXAMINER 2/12/04 DATE CONSIDERED

PTO-1	449 P	EPRODUCED		Sheet 9	of 16
	447 6	EFRODUCED	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	
	IN	SECOND SUPPLEMENTAL FORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a		
		April 2, 2003	FILING DATE	CONFIRMATION NO.	anovin
	(ט	se several sheets if necessary)	March 30, 2001	7248	GROUP 1615
	-, -	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	Pages, Etc.)	
	BR				
M	BS	Adjei, A., and Garren, J., "Pr Particle Size on Bioavailabil Volunteers," Pharm. Res., 7(6)		ide Drugs: Effe in Healthy Mal	ct of e
	BT	Allen, T.M., et al., "Subcutar with the Intravenous and Intra Biophys. Acta. 1150:9-16 (1993		iposomes: A Com ection," Bioche	parison m. et
	BU	Altshuler, B., et al., "Aeroso Am. Med. Assoc. Arch. of Indus	ol Deposition in the Human st. Health 15:293-303 (195	n Respiratory Tr	ract,"
	BV	Anderson, P.J., et al., "Effect Boluses," Am. Rev. Respir. Dis	t of Cystic Fibrosis on a		
_	BW	Anderson, M., et al., "Human D Inhaled with an Extremely Low	enosition and di-	of 6-µm Particle	:s (1995).
	вх	Barrera, D.A., et al., "Synthe Biodegradable Copolymer: Poly(115:11010-11011 (1993).	sis and DOD Domeile was		
	BY	Beck, L.R., et al., "A New Long Administration of Progesterone (1979).	g-Acting Injectable Micro ," Fertility and Sterilit	capsule System y, 31(5):545-55	for the
	BZ	Benita, S., et al., "Characteri Microspheres," J. of Pharm. Sc:	ization of Drug-loaded Po i 73(12):1721-1724 (1984)	ly(d,1-lactide)	
	BR2	Blackett, P.M., and G. Buckton, Interaction of Surfactants with Salbutamol Sulphate in a Model Research, 12(11):1689-1693 (199	"A Microcalorimetric Invalorimetric	vestigation of	
	BS2	Brain, J.D., "Physiology and Pa The Reticuloendothelial System, York), pp. 315-327 (1985).	thonhysiology of Duly	y Macrophages". s. (Plenum Pres	In s, New
	BT2	Brown, A.R., et al., "Propellan Potential Therapeutic Agents in 28:241-257 (1994).	t-Driven Aerosols of Func the Respiratory Tract,"	tional Proteins Immunopharmacol	as ogy,
1	BU2	Byron, P.R., "Determinants of Dr Aerosols Delivered to the Lung,"	rug and Polypeptide Bioav " Adv. Drug. Del. Rev., 5	ailability from :107-132 (1990)	
1	BV2	Carroll, B.A., et al., "Gelatin Ultrasonic Contrast Agents," Inv	Encapsulated Nitroger Wi		
F	3W2	Carroll, B.A., et al., "Ultrasor Encapsulated Microbubbles," Radi	ic Contract Enhancement		
В	X2	Ch'ng, H.S., et al., "Bioadhesiv Drug Delivery II: Synthesis and Bioadhesive Polymers," J. of Pha	re Polymers as Platforms f	or Oral Contro	lled luble
MINER	{ 	AML DA'	TE CONSIDERED 2/12/04		

E

			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
PTO-14	49 REPR	RODUCED	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	,
		SECOND SUPPLEMENTAL	3303.2003	37,022,710	
	INFO	RMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT	_ 7	
			David A. Edwards, et a	31.	
		April 2, 2003	FILING DATE	CONFIRMATION NO.	GROUP
	(Use	e several sheets if necessary)	March 30, 2001	7248	1615
		OTHER DOCUMENTS (Including Aut	thor, Title, Date, Pertinent	Pages, Etc.)	
M	BY2	Clark, A., and P. Byron, "Dep Aerosol Particle Size," Z. Er			on
	BZ2	Clark, A.R., and M. Egan, "Mo Aerosols," J. Aerosol Sci., 2	deling the Deposition of		ed Drug
	BR3	Clay, M.M., et al. "Effect of Nebulised Terbutaline in Asth	Aerosol Particle Size on		
	BS3	Cohen, S., et al., "Controlle Poly(Lactic/Glycolic Acid) Mi	d Delivery Systems for Pr crospheres," Pharm. Res.	oteins Based on 8(6):713-720(19	ı 91).
	втз	Colthorpe, P., et al., "The A Comparison of Intratracheal Pharm. Res. 9(6):764-768 (199	and Aerosol Administrati	nary-Delivered on to the Rabbi	Insulin: t,"
	BU3	Daly, W.H., et al., "The Prepusing Bis(Trichloromethyl) Car(1988).	aration of N-Carboxyanhyd rbonate," Tetrahedron Let	rides of α-Amin t., 29(46):5859	o Acids -5862
	BV3	Damms, B. and W. Bains, "The Controlled Release, 8-11 (199		without Needles	," J.
	вwз	Darquenne, C., and M. Paiva, Transport and Deposition in A. Physiology, 80(4):1401-1414 (lveolar Zone of Human Lung	l Simulations o g," Journal of	f Aerosol Applied
	вхз	Davies, C.N., et al., "Breath: J. of Appl. Physiol. 32(5):59	ing of Half-micron Aeroso 1-600(1972).	ls. I. Experime	ntal.,"
	вуз	Davis, S.S., and L. Illum, "Po Biomaterials, 9:111-115 (1988)	olymeric Microspheres as I	Orug Carriers,"	
	BZ3	Davis, S.S., et al., "Microsph Parenteral and Nasal Administr 15, pp. 201-213 (1987).	-	_	Chapter
M	BR4	Dorries, A.M., and Valberg P.A. Versus Instilled Material," An	A., "Heterogeneity of Phag n. Rev. Respir. Dis., 146:	gocytosis for I 831-837 (1992)	nhaled
	BS4	This reference number intentional	ly left blank.		
	BT4	This reference number intentional	ly left blank.		
M	BU4	Eldridge, J. H., et al., "Biod System," Mol. Immunol., 28(3):	egradable Microspheres as	a Vaccine Del:	ivery
	BV4	Feinstein, S.B., et al., "Two-Vitro Development and Quantita 3(1):14-20 (1984).	Dimensional Contrast Echo tive Analysis of Echo Con	cardiography I trast Agents,"	. In <i>JACC</i>
V	BW4	Ferin, J., et al., "Pulmonary Rats," Am. J. Respir. Cell Mol	Retention of Ultrafine an . Biol. 6:535-542 (1992).	d Fine Particle	es in
EXAMIN	ER	Alle	DATE CONSIDERED $2/12/0$	4	

				Sheet 11	of 16
PTO-	1449 R	SECOND SUPPLEMENTAL	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	
	IN	FORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a	12.	
	(11	April 2, 2003 (se several sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO.	GROUP
			<u> </u>		1615
	ВХ	OTHER DOCUMENTS (Including Au			
\mathcal{N}		Findeisen, W. "Uber Das Abset Der Menshlichen Lunge Bei Der 379 (1935).	zen Kleiner, in Der Luft : Atmung," Pflugers Arch.	Suspendierter Te D. Ges. Physiol	eilchen . 236:36
	BY	This reference number intentional	lly left blank.		
M	BZ4	Ganderton, D., "The Generation Aggregates," J. Biopharmaceut.	n of Respirable Clouds For ical Sciences, 3(1/2):101-	rm Coarse Powder -105 (1992)	•
M	BRS		and Inhalad Daniel		irways: und Tech.
M	BS5	Gerrity, T.R., et al., "Calcul Airway Generations of Normal S	ated Deposition of Inhale Subjects," J. Appl. Phys.,	d Particles in	the (1979).
	BT5	This reference number intentional	ly left blank.		
M	BU5		lies and Future December	in the Delivery act," Adv. Drug	of Del.
	BV5	This reference number intentional	ly left blank.		
7	BW5	Gonda, I., "Targeting by Depos. Technology (ed. A.J. Hickey), I	ition " in Di-	Inhalation Aers	sol
η	BX5	Gurny, R., et al., "Bioadhesive Analysis," Biomaterials, 5:336-	- Intraoral Polones Gunta	ns: Design, Test	ing and
	BY5	This reference number intentionall	y left blank.		·
	BZ5	This reference number intentionall	y left blank.		
	BR6	Heyder, J., and G. Rudolf, "Mathuman respiratory tract," J. Ae	hematical models of	cle deposition	in the
	BS6	Heyder, J., et al., "Total Depo Respiratory Tract for Nose and (1975).	sition of Navaral Barrier		-328
	BT6	Hickey, A.J., et al., "Use of Porugs from Dry Powder Aerosols," (1992).	article Morphology to Inf. " J, Biopharmaceutical Sc.	luence the Delivi., 3(%):107-113	very of
\int	BU6	Hirano, S., et al., "Pulmonary (into the Rat Lung," Arch. of Tox	Clearance and Toxicity of xicology, 63:336-342 (1989	Zinc Oxide Inst	illed
\perp		Hrkach, et al., "Synthesis of Po Copolymers," Macromolecules, 28	oly/I lastic sail		
MINE		0.11	TE CONSIDERED 2/12/09	of the state of th	
			, , ,		اا
				•	

.. .

. .

<u>\</u>

Ä

				Sheet 12 of 16
PTO-14	49 REP	RODUCED	ATTORNEY DOCKET NO. 2685.1003-008	application NO. 09/822,716
		SECOND SUPPLEMENTAL		
	INFC	RMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT David A. Edwards, et a	a1.
		April 2, 2003		
,	///	-	FILING DATE March 30, 2001	CONFIRMATION NO. GROUP 7248 1615
	(Use	s several sheets if necessary)		
	-	OTHER DOCUMENTS (Including Au		
M	BW6	Hrkach, J.S., et al., "Poly(L Class of Functional Biodegrad Polymers for Bioapplications, Ottenbrite, et al., Eds., Ame: 1996.	able Biomaterials" in Hyd ACS Symposium Series No.	drogels and Biodegradable 627, Raphael M.
	BX6	Illum, L., et al., "Bioadhesi" System," Int. J. of Pharm. 39	ve Microspheres as a Pote :189-199 (1987).	ntial Nasal Drug Delivery
	ву6	Johnson, M.A., et al. "Deliver Nebulizer Systems in Chronic & Chest, 96:6-10 (1989).	ry of Albuterol and Iprat Stable Asthma: Efficacy a	rophiumbromide from Two nd Pulmonary Deposition,"
	BZ6	Kao, Y.J., and R.L. Juliano, Reticuloendothelial System, Ed Clearance of Large Unilamellar 461 (1981).	ffects of Reticuloendothe	lial Blockade on the
m	BR7	Kassem, N.M., and D. Gandertor Characteristics of Inspirable 42(Supp):11 (1990).	n, "The Influence of Carr Powder Aerosols," <i>J. Pha</i>	ier Surface on the rm. Pharmacol.,
	BS7	This reference number intentional	ly left blank.	
\overline{n}	BT7	Kobayashi, S. et al., "Pulmona Containing Absorption Enhancer	ary Delivery of Salmon Cars in Rats," Pharm. Res.,	lcitonin Dry Powders 13(1):80-83 (1996).
	BU7	Kohler, D., "Aerosols for Syst	emic Treatment" Lung, Su	ppl: pp. 677-684 (1990).
m	BV7	Komada, F. et al., Intratrache Absorption from Solution and E 863-867 (June, 1994).	eal Delivery of Peptide and Pry Powder by Rat Lung," .	nd Protein Agents: J. Pharm. Sci., 83(6):
	BW7	This reference number intentional	ly left blank.	
\overline{M}	BX7	Kricheldorf, H.R. "α-Aminoacid Springer-Verlag, Berlin (1987)	-N-Carboxy-Anhydrides and	d Related Heterocycles,"
	BY7	Kwok, K.K., et al., "Productio Microcapsules by an Air Atomiz (1991).	n of 5-15 μ m Diameter Algarian Technique," Pharm.	ginatė Polylysine Res., 8(3):341-344
	BZ7	Lai, Y-L., et al., "Sustained Poly(Glycolide-co-Lactide) Mic	Bronchodilation with Isoprospheres," Pharm. Res.,	oroterenol 10(1):119-125 (1993).
	BR8	Lai, W.C., et al., "Protection Genetic Vaccination," DNA and	Against Mycoplasma Pulmi Cell Biology, 14(7):643-6	inosis Infection by 551 (1995).
	BS8	Landahl, "On The Removal of Ai I. The Lung," Bull. Math. Biop.	r-borne Droplets by The H hys., 12:43-56 (1950).	uman Respiratory Tract:
	втв	Langer, R., "New Methods of Dr	ug Delivery", Science, 24	9:1527-1533 (1990).
M	BU8	Le Corre, P., et al., "Prepara Polylactide and Polylactide-Co Pharmaceutics, 107:41-49 (1994)	-Glycolide Microspheres,"	of Bupivacaine-Loaded Int. J. of
NIMAX	ER C	All (DATE CONSIDERED 2/12/	104

1					of 16
[[PRODUCED	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO.	
	7177	SECOND SUPPLEMENTAL	2665.1003-008	09/822,716	
H	INF	ORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT		
		April 2, 2003	David A. Edwards, et	al.	
	/tre		FILING DATE March 30, 2001	CONFIRMATION NO.	GROUP
<u> </u>	(0)	se several sheets if necessary)		7248	1615
	BV8	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	Pages, Etc.)	
1) 508	Leone-Bay, A., et al., "Micr Amino Acids: Properties, Mol calcitonin," J. of Med. Chem	osphere Formation in a Se ecular Modeling, and Oral ., 38(21):4257-4262 (1995	ries of Derivat Delivery of Sa).	ized α- lmon
M	BW8	Liu, F., et al., "Pulmonary Res. 10(2):228-232 (1993).	Delivery of Free and Lipo	somal Insulin,"	Pharm.
\mathcal{N}	BX8	Liu, W.R., et al., "Moisture the Solid State," Biotechnol	-Induced Aggregation of Ly . and Bioeng., 37:177-184	yophilized Prote (1991).	eins in
	BY8	This reference number intentiona	ally left blank.		
\mathcal{M}	BZ8	Martonen, T.B., "Mathematical Pharmaceuticals", J. of Pharm	Model for the	Deposition of I	nhaled
	BR9	Masinde, L.E., and Hickey, A. Lactic Acid) Microspheres," I	T 102		Poly(L
	BS9	Mathiowitz, E., et al., "Nove Polymers, 6:275-283 (1987).	l Microcapsules for Deliv	ery Systems," R	eactive
	ВТ9	Mathiowitz, E., et al., "Poly Characterization of Systems Ma 45:125-134 (1992).	anhydride Microspheres. I'ade by Spray Drying," J. o	V. Morphology a of Appl. Polyme	nd r Sci.
_	BU9	Mathiowitz, E., et al., "Morph ASystems," Scanning Microscopy	hology of Polyanhydride Mi	icrosphere Deliv	very
	BV9	Mathiowitz, E., and R. Langer	er, "Polyanhydride Microspheres as Drug Carriers," J. of Controlled Release 5:13-22 (1987).		
	BW9	Mathiowitz, E., et al., "Polya Microencapsulation by Solvent (1988).	an has and and all a sections.		
η	вхэ	Ménache, M.G., et al., "Partic Laboratory Animals," Annals of	le Inhalability Curves fo	r Humans and Sm	all
	BY9	This reference number intentionall	ly left blank	(3), (31) 2320 (19	23).
η	BZ9	Morimoto, Y., and Adachi, Y., Phosphatidylcholine Upon Intrat Bull. 30(6):2248-2251 (1982).	WD: 2 man and 12	somal D Rats," Chem	Pharm.
η	BR10	Mulligan, R.C., "The Basic Scie (1993).	ence of Gene Therapy", Sci	ence, 260:926-9	32
I	BS10	This reference number intentionally	y left blank.		
E		This reference number intentionally			
7	3U10 1	Newman, S.P., "Therapeutic Inha 76(5):194-207 (1984).		," Inhalation T	herapy,
MINE		10001	TE CONSIDERED 2//2/0		/

		SECOND SUPPLEMENTAL	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716	
	INI	FORMATION DISCLOSURE CITATION IN AN APPLICATION April 2, 2003	APPLICANT David A. Edwards, et	al.	
	(U:	se several sheets if necessary)	FILING DATE March 30, 2001	CONFIRMATION NO.	GROUP
				7248	1615
) BVI	Newman, S.P., "Aerosol Depo Chest, 88(2):152S-160S (198	Author, Title, Date, Pertinentsion Considerations in	It Pages, Etc.) Inhalation Thera	
	BW1		11	rosolized and chG-CSF," Pharm.	Res.,
1	BX1	Niven, R.W., et al., "Solute Lung. III. Absorption of Ser Poly' (2-Hydroxyethyl) -Aspart	e Absorption From the Airw veral Peptidase-Résistant, tamides," Pharm. Res., 7(1	ways of the Isolo Synthetic Poly (0):990-994 (1990	ated Rat
_	BY1	Niwa, T., et al., "Aerosoliz Nanospheres for Pulmonary De 115(9):732-741 (1995).	zation of Lactide/Glycolid elivery of Peptide-Drugs,"	e Copolymer (PLO Yakugaku Zasshi	GA) i,
\perp	BZ10	Ogiwara, M., "Clearance and M Impaired Liver of Rat," Gast	aximum Removal Rate of Li	posomes in Norma	l and
$\underline{\gamma}$	BR11	Okumura, K., et al., "Intrat Solution and Aerosol by Rat			
	BS11	This reference number intention	ally left blank.	105, 88:63-73 (1	992).
	BT11		147-1471	elivered peptide ermones," J. Con	s and trolled
	BU11	Pavia, D., "Lung Mucociliary and Experimental Aspects, Cla London), pp. 127-155, (1984).	Clearance". In Aerosols arke, S.W. and Pavia, D.,	and the Lung: C eds.(Butterworth	linical ns,
	BV11	Peart, J. et al., "Multicompo Aerosols," J. Pharm. Res. 14(s in Dry Powder	
	BW11	Pinkerton, K.E., et al., "Aer Lung Using Confocal Scanning 26:437-443 (1993).	0-01/ 1		d in the
4	BX11	Rudt, S., and R.H. Muller, "In Microparticles by Chemilumines Particle Size and Particle Con	centration," J. Contr. Re	tical Parameter: 1., 22:263-271	(1992)
	BY11	Rudt, S., et al., "In Vitro Ph Chemiluminescence. IV. Effect with Poloxamine and Antarox CO 25:123-132 (1993).	agocytosis Assay of Nano-	and Micropartic	cles by
4		Ruffin, R.E., et al., "The Pre and Propranolol in Asthmatic P		-907 (1981).	
_		Sela, M., et al., "Multichain (1956).	Polyamino Acids," J. Am.	Chem. Soc., 78:	746-751
		Smith, A.L., and B. Ramsey, "Ae Respiration, 62(suppl 1):19-24	erosol Administration of A	untibiotics,"	
INER		OA A	ATE CONSIDERED		

٠,

25

PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 2685.1003-008 09/822,716 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION APPLICANT IN AN APPLICATION David A. Edwards, et al. April 2, 2003 FILING DATE CONFIRMATION NO. GROUP March 30, 2001 (Use several sheets if necessary) 7248 1615 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Smith, P.L., "Peptide Delivery via the Pulmonary Route: A Valid Approach for BT12 NLocal and Systemic Delivery," J. of Contr. Rel., 46:99-106 (1997). Strand, S.E., and L. Bergqvist, "Radiolabeled Colloids and Macromolecules in BU12 the Lymphatic System," Critical Reviews in Therapeutic Drug Carrier Systems, 6(3):211-238 (1989) Swift, D., "The Oral Airway - A Conduit or Collector for Pharmaceutical. Aerosols?" Respiratory Drug Delivery IV, 187-195 (1994). Tabata, Y., et al., "Controlled Delivery Systems for Proteins Using RW12 Polyanhydride Microspheres," Pharm. Res. 10(4):487-496 (1993). Tabata, Y., and Y. Ikada, "Effect of Surface Wettability of Microspheres on BX12 Phagocytosis," J. of Colloid and Interface Sci., 127(1):132-140 (1989). Tabata, Y., and Y. Ikada, "Macrophage Phagocytosis of Biodegradable BY12 Microspheres Composed of L-lactic Acid/glycolic Acid Homo- and Copolymers," J. of Biomed. Mater. Res., 22:837-858 (1988). Tabata, Y., and Ikada, Y., "Effect of Size and Surface Charge of Polymer Microspheres on Their Phagocytosis by Macrophage, " J. Biomed. Mater. Res., 22:837-843 (1988). Taburet, A.M., and Schmit, B., "Pharmacokinetic Optimisation of Asthma Treatment," Clin. Pharmacokinet. 26(5):396-418 (1994). Tansey, I.P., "The Challenges in the Development of Metered Dose Inhalation Aerosols Using Ozone-Friendly Propellants," Spray Technol. & Market, 4:26-29 Timsina, M.P., et al., "Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers," Int. J. of Pharm., 101:1-13 (1994). Turner, J.R., and S.V. Hering, "Greased and Oiled Substrates as Bounce-Free BU13 Impaction Surfaces," J. Aerosol Sci., 18(2):215-224 (1987). BV13 This reference number intentionally left blank. BW13 Wall, D.A., "Pulmonary Absorption of Peptides and Proteins," Drug Delivery, 2:1-20 (1995). BX13 Warheit, D.B., and Hartsky, M.A., "Role of Alveolar Macrophage Chemotaxis and Phagocytosis in Pulmonary Clearance to Inhaled Particles: Comparisons Among Rodent Species," Microscopy Res. and Tech., 26:412-422 (1993). Weiner, Norman et al., "Liposomes as a Drug Delivery System," Drug Development and Industrial Pharmacy, 15(10):1523-1554 (1989). Wheatley, M.A., et al., "Contrast Agents for Diagnostic Ultrasound: Development and Evaluation of Polymer-Coated Microbubbles," Biomaterials 11:713-717 BR14 Wichert, B., and Rohdewald, P., "Low Molecular Weight PLA: A Suitable Polymer for Pulmonary Administered Microparticles?," J. Microencapsulation, 10(2):195-207 (1993). EXAMINER DATE CONSIDERED 2/12/04

PTO-1449 REPRODUCED			Sheet 16 of 16			
		SECOND SUPPLEMENTAL	ATTORNEY DOCKET NO. 2685.1003-008	APPLICATION NO. 09/822,716		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT David A. Edwards, et al.			
April 2, 2003 (Use several sheets if necessary)			FILING DATE March 30, 2001	CONFIRMATION NO.	GROUP 1615	
OTHER DOCUMENTS (Including Au					1015	
M	B\$14	Wong, M., and Suslick, K.S., Microbubbles," Mat. Res. Soc.	"Company"	· · · · · · · · · · · · · · · · · · ·		
	BT14	Zanen, P., et al., "The Option Mild Asthmatics", Int. J. of	nol Devetical at		ols in	
	BU14	Zanen, P., et al., "The Optimal Particle Size for Parasympathicolytic Aerosols in Mild Asthmatics", Int. J. of Pharm., 114:111-115 (1995).				
	BV14	Zeng, X.M., et al., "The Cont Pharm., 124:149-164 (1995).	rolled Delivery of Drugs to the Lung," Int. J. of			
M	Zeng, X.M., et al., "Tetrandrine Delivery to the Lung: The Optimisa Albumin Microsphere Preparation by Central Composite Design," Int. Pharm., 109:135-145 (1994).					
					· .	
					·	
_						
ļ						
	+					
AMINER		AAA DA	TE CONSIDERED 2/12/04	<u></u>		
		U	110/0/		- 11	